🧵 Among patients with early #ParkinsonDisease, treatment with nicotinamide riboside for 52 weeks did not improve clinical outcomes vs placebo and was associated with worse change in overall Movement Disorder Society Unified Parkinson Disease Rating Scale scores.
These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease.
ja.ma/4zTRLKL
These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease.
ja.ma/4zTRLKL